Crossref
FDA Revokes Approval for Preterm Birth Drug Makena
JAMA · 2023
DOI: 10.1001/jama.2023.6257 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: 17 alpha-Hydroxyprogesterone Caproate, Premature Birth, Drug Recalls, Reproductive Control Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
17 alpha-Hydroxyprogesterone CaproatePremature BirthDrug RecallsReproductive Control AgentsFemaleHumansInfant, NewbornDrug ApprovalUnited StatesUnited States Food and Drug Administration
Substanzen
17 alpha-Hydroxyprogesterone CaproateReproductive Control Agents
Zitieren
APA
Harris, E. (2023). FDA Revokes Approval for Preterm Birth Drug Makena. JAMA. https://doi.org/10.1001/jama.2023.6257
Vancouver
Harris E. FDA Revokes Approval for Preterm Birth Drug Makena. JAMA. 2023. doi:10.1001/jama.2023.6257
BibTeX
@article{Harris2023,
author = {Harris, Emily},
title = {FDA Revokes Approval for Preterm Birth Drug Makena},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.6257}
}
EUVIMED